Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current Opinion in Rheumatology

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.bor.0000144760.37777.faPMID 15577611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.

  2004cited by this paper
• Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.

  2004cited by this paper
• Blunted coronary flow reserve in systemic sclerosis.

  2004cited by this paper
• Anti-DNA topoisomerase IIα autoantibodies in localized scleroderma

  2004cited by this paper
• The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma.

  2004cited by this paper
• A study of the prevalence of systemic sclerosis in northeast England.

  2004cited by this paper
• Nephrogenic fibrosing dermopathy

  2004cited by this paper
• Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.

  2004cited by this paper
• Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma.

  2004cited by this paper
• HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities.

  2003cited by this paper
• The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis.

  2003cited by this paper
• Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis.

  2003cited by this paper
• The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis.

  2003cited by this paper
• Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

  2003cited by this paper
• The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma.

  2003cited by this paper
• Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

  2003cited by this paper
• Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies.

  2003cited by this paper
• More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis.

  2003cited by this paper
• Autoantibodies in patients with systemic sclerosis and cancer: a case-control study.

  2003cited by this paper
• Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies.

  2003cited by this paper
• Raynaud’s phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?

  2003cited by this paper
• Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.

  2003cited by this paper
• Antiphospholipid antibody in localised scleroderma

  2003cited by this paper
• A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.

  2003cited by this paper
• Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations

  2002cited by this paper
• Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

  2002cited by this paper
• Protein-protein interactions between human exosome components support the assembly of RNase PH-type subunits into a six-membered PNPase-like ring.

  2002cited by this paper
• Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis.

  2002cited by this paper
• Scleroderma overlap syndromes.

  2002cited by this paper
• Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases

  2002cited by this paper
• Identity of the RNase MRP- and RNase P-associated Th/To autoantigen.

  2002cited by this paper
• Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients.

  2002cited by this paper
• Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival

  2002cited by this paper
• Anti-U1RNP antibodies in patients with localized scleroderma

  2001cited by this paper
• Anti-U3 snRNP antibodies in localised scleroderma.

  2001cited by this paper
• Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants.

  2001cited by this paper
• Autoantibodies against DNA double-strand break repair proteins.

  2001cited by this paper
• Autoantibody profiles in the sera of European patients with myositis

  2001cited by this paper
• Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP

  2001cited by this paper
• Renal vascular damage in Japanese patients with systemic sclerosis.

  2001cited by this paper
• Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.

  2001cited by this paper
• Retrocalcaneal bursitis in polymyalgia rheumatica

  2001cited by this paper
• Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.

  2001cited by this paper
• Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus.

  2001cited by this paper
• Anti-fibrillarin antibodies in systemic sclerosis.

  2001cited by this paper
• Clinical Spectrum of Raynaud's Phenomenon in Patients Referred to Vascular Clinic

  2000cited by this paper
• Anti‐topoisomerase II α autoantibodies in systemic sclerosis—association with pulmonary hypertension and HLA‐B35

  2000cited by this paper
• Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin).

  2000cited by this paper
• Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome.

  2000cited by this paper
• Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis

  2000cited by this paper
• Anticentromere Antibody as a Risk Factor for Cancer in Patients with Systemic Sclerosis

  2000cited by this paper
• Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation.

  1999cited by this paper
• Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases.

  1999cited by this paper
• Distribution and antigen specificity of anti‐U1RNP antibodies in patients with systemic sclerosis

  1999cited by this paper
• Scleroderma overlap syndromes.

  1999cited by this paper
• Mixed connective tissue disease.

  1999cited by this paper
• A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients.

  1999cited by this paper
• Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment.

  1998cited by this paper
• Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients.

  1998cited by this paper
• Mapping of topoisomerase II α epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis

  1998cited by this paper
• Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay.

  1998cited by this paper
• Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.

  1998cited by this paper
• Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

  1998cited by this paper
• HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies.

  1998cited by this paper
• HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients.

  1998cited by this paper
• Abnormal IgG cardiolipin antibody titers in patients with Raynaud's phenomenon and/or related disorders: prevalence and clinical significance.

  1998cited by this paper
• African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.

  1998cited by this paper
• [Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma].

  1997cited by this paper
• Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives.

  1997cited by this paper
• Sclérodermie systémique et cancer. Recherche de facteurs prédictifs de cancer chez 123 patients sclérodermiques

  1997cited by this paper
• Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome.

  1997cited by this paper
• Autoantibody formation after allogeneic bone marrow transplantation: Correlation with the reconstitution of CD5+ B cells and occurrence of graft‐versus‐host disease

  1997cited by this paper
• Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases.

  1997cited by this paper
• Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation

  1997cited by this paper
• Antiendothelial cell antibodies: useful markers of systemic sclerosis.

  1997cited by this paper
• Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis.

  1996cited by this paper
• Specificity of antinuclear antibodies in scleroderma‐like chronic graft‐versus‐host disease: clinical correlation and histocompatibility locus antigen association

  1996cited by this paper
• Follow-up of 151 patients with high-titer U1RNP antibodies

  1996cited by this paper
• Characterization of Human DNA Topoisomerase II as an Autoantigen Recognized by Patients With IDDM

  1996cited by this paper
• Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis.

  1996cited by this paper
• The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.

  1996cited by this paper
• Measurement of anticardiolipin antibodies by ELISA using β2‐glycoprotein I (β2‐GPI) in systemic sclerosis

  1996cited by this paper
• Incidence of cancer among patients with systemic sclerosis

  1995cited by this paper
• Longitudinal study of anticentromere and antitopoisomerase-I isotypes.

  1995cited by this paper
• Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus

  1995cited by this paper
• Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis.

  1995cited by this paper
• Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities.

  1995cited by this paper
• Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.

  1994cited by this paper
• Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis

  1993cited by this paper
• Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis.

  1993cited by this paper
• Cancer in systemic sclerosis.

  1993cited by this paper
• Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study.

  1993cited by this paper
• Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.

  1992cited by this paper
• Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases.

  1992cited by this paper
• Association of anti-topoisomerase I with cancer.

  1992cited by this paper
• Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku.

  1992cited by this paper
• The Clinical and Immunogenetic Features of Patients with Autoantibodies to the Nucleolar Antigen PM-Scl

  1992cited by this paper
• Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis.

  1992cited by this paper
• Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.

  1991cited by this paper
• An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs.

  1991cited by this paper

• Clinical impact and prognosis of cryoglobulinemia and cryofibrinogenemia in systemic sclerosis.

  2022cites this paper
• Development of Pulmonary Hypertension in Over One‐Third of Patients With Th/To Antibody–Positive Scleroderma in Long‐Term Follow‐Up

  2022cites this paper
• Clinical characteristics associated with small airways disease in systemic sclerosis

  2022cites this paper
• Clinical and Prognostic Characteristics of "Disease-specific" Autoantibodies in Systemic Scleroderma

  2021cites this paper
• Distinct T cell chromatin landscapes in scleroderma subtypes

  2021cites this paper
• Clinical and Histopathological Features of Scleroderma-like Disorders: An Update

  2021cites this paper
• Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

  2021influential citation
• Anti–Polymyositis/Scl Antibodies in Systemic Sclerosis

  2021cites this paper
• Sclerodermalike syndromes: Great imitators.

  2020cites this paper
• Biomarkers of skin and lung fibrosis in systemic sclerosis

  2019cites this paper
• Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis

  2019cites this paper
• Digital Ulcerations and Classification of SSc Subsets and Overlap Syndromes

  2018cites this paper
• Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives

  2018cites this paper
• Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study

  2018cites this paper
• Diagnostic criteria, severity classification and guidelines of systemic sclerosis

  2018cites this paper
• Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis

  2018cites this paper
• The Clinical Relevance of Antifibrillarin (anti‐U3‐RNP) Autoantibodies in Systemic Sclerosis

  2017cites this paper
• Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

  2017cites this paper
• Autoantibodies in Systemic Sclerosis

  2016cites this paper
• Systemic sclerosis (Scleroderma) Among Adults Attending the Rheumatology Clinic of a Tertiary Institution

  2016cites this paper
• The clinical relevance of anti-fibrillarin (anti U3-RNP) autoantibodies in systemic sclerosis Short title: Anti-fibrillarin in systemic sclerosis

  2016cites this paper
• 全身性強皮症 診断基準・重症度分類・診療ガイドライン

  2016cites this paper
• Challenges and opportunities in treating inflammation associated with pulmonary hypertension

  2016cites this paper
• SVEUČILIŠTE U ZAGREBU MEDICINSKI FAKULTET

  2015cites this paper
• Determining respiratory impairment in connective tissue disease-associated interstitial lung disease.

  2015cites this paper
• Utility of autoantibodies as biomarkers for diagnosis and staging of neurodegenerative diseases.

  2015cites this paper
• Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique

  2015cites this paper
• FACULTE DE MEDECINE ET DE PHARMACIE DE ROUEN

  2015cites this paper
• The Evaluation of ANA and dsDNA results in patient with suspected autoimmune disease

  2015cites this paper
• Fibrosis—a lethal component of systemic

  2014cites this paper
• STEM CELLS ARE HIGHLY ENRICHED SOURCES OF AUTOANTIGENS TARGETED IN SCLERODERMA – IMPLICATIONS FOR PATHOGENESIS

  2014cites this paper
• Fibrosis—a lethal component of systemic sclerosis

  2014cites this paper
• Increased bone mineral density at the hypoxia prone site of the juxta-articular metacarpal bone in patients with limited systemic sclerosis: a cross-sectional study.

  2014cites this paper
• Chapter 38 – Fibrillarin Autoantibodies

  2014cites this paper
• Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis

  2014cites this paper
• Biologics in systemic sclerosis.

  2014cites this paper
• Новые классификационные критерии системной склеродермии (лекция)

  2013cites this paper
• Transplantation rénale dans le cadre de la sclérodermie systémique : étude française multicentrique

  2013cites this paper
• Clinical and Radiographic Heterogeneity of Interstitial Lung Disease in Systemic Sclerosis Based on Disease-Specific Autoantibodies

  2013cites this paper
• Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells

  2013cites this paper
• [Autoantibodies and their clinical characteristics in systemic sclerosis].

  2013cites this paper
• Autoantibodies in systemic sclerosis.

  2013cites this paper
• Associations with Organ Involvement and Autoantibodies in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group (CSRG)

  2013cites this paper
• Increased production of a proliferation-inducing ligand (APRIL) by the peripheral blood mononuclear cells predicts worse prognosis in patients with systemic sclerosis

  2012cites this paper
• Ранняя системная склеродермия -современный алгоритм диагностики (лекция)

  2012cites this paper
• Systemic sclerosis – prognostic factors, disease activity and severity

  2011influential citation
• Biomarkers in the Management of Scleroderma: An Update

  2011cites this paper
• Caractérisation de l'interaction de l'auto-antigène ADN topoisomérase I avec les fibroblastes dans la sclérose systémique

  2011cites this paper
• Coagulation and autoimmunity in scleroderma interstitial lung disease.

  2011cites this paper
• Juvenile Systemic Sclerosis

  2011cites this paper
• Clinical and Laboratory Evaluation of Systemic Rheumatic Diseases

  2011cites this paper
• Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

  2011cites this paper
• Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis

  2010cites this paper
• Serum Endoglin Levels in Patients Suffering from Systemic Sclerosis and Elevated Systolic Pulmonary Arterial Pressure

  2010cites this paper
• Increased Production of a Proliferation-inducing Ligand (APRIL) by Peripheral Blood Mononuclear Cells Is Associated with Antitopoisomerase I Antibody and More Severe Disease in Systemic Sclerosis

  2010cites this paper
• Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea

  2010cites this paper
• Asociación entre manifestaciones clínicas de enfermedades autoinmunes con los polimorfismos de PTPN22, STAT4, CTLA-4 en población colombiana

  2010cites this paper
• The prognostic factors of systemic sclerosis for survival among Koreans

  2010cites this paper
• Pruritus in Autoimmune Diseases

  2010cites this paper
• Consenso sobre Esclerodermia

  2009cites this paper
• Assessment of the correlation between the activity of anti-cyclic citrullinated peptide IgG, topoisomerase I, and centromere proteins in Mexican patients with progressive systemic sclerosis

  2009cites this paper
• Analyse der diagnostischen Wertigkeit krankheitsspezifischer Antikörper bei Patienten mit systemischer Sklerose

  2009cites this paper
• BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians

  2009cites this paper
• Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis.

  2009cites this paper
• Expression and regulation of monocyte chemoattractant protein-3 (MCP-3) in fibrosis

  2009cites this paper
• Chapter 21 – Scleroderma and Related Disorders

  2009cites this paper
• B cells and transplantation: an educational resource.

  2009cites this paper
• Evaluación de la correlación de la actividad de IgG sérica contra péptido citrulinado cíclico, topoisomerasa I y proteínas de centrómero en pacientes mexicanos con esclerosis sistémica progresiva

  2009cites this paper
• Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells.

  2009cites this paper
• SOCIEDAD ARGENTINA DE DERMATOLOGÍA

  2008cites this paper
• Scleroderma-like disorders.

  2008cites this paper
• Scleroderma.

  2008cites this paper
• The immunobiology of systemic sclerosis.

  2008cites this paper
• Connective Tissue Disease Associated Pulmonary Hypertension

  2008cites this paper
• Two Cases of Juvenile Systemic Sclerosis and Literature Review

  2007cites this paper
• Chapter 9 Juvenile Systemic Sclerosis

  2007cites this paper
• Update on autoantibodies in systemic sclerosis

  2007cites this paper
• Localized scleroderma and systemic sclerosis: is there a connection?

  2007cites this paper
• Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis

  2007influential citation
• The development of systemic sclerosis classification criteria

  2007cites this paper
• 42 – FIBRILLARIN AUTOANTIBODIES

  2007cites this paper
• TOPOISOMERASE-I (SCL-70) AUTOANTIBODIES

  2007cites this paper
• 18 – ANTINUCLEOLAR ANTIBODIES

  2007cites this paper
• Anti‐p53 antibodies in patients with systemic sclerosis

  2007cites this paper
• Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.

  2007cites this paper
• An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis.

  2007influential citation
• Two Cases of Juvenile Systemic Sclerosis and Literature Review

  2007influential citation
• Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement.

  2007cites this paper
• [Scleroderma associated autoantibodies - clinical and diagnostic relevance].

  2006cites this paper
• Skin disease: a cardinal feature of systemic sclerosis.

  2006cites this paper
• Avian models with spontaneous autoimmune diseases.

  2006influential citation
• Sklerodermie-assoziierte Autoantikörper – klinische und diagnostische Relevanz

  2006influential citation
• Thyroid status in patients with systemic sclerosis.

  2006cites this paper
• Auto-anticorps stimulateurs du recepteur pdgf utilises comme marqueur pathologique et comme cible therapeutique

  2006cites this paper
• Autoantibodies and Skin Involvement in Systemic Autoimmune Diseases

  2006cites this paper
• Is scleroderma an autoantibody mediated disease?

  2006cites this paper
• Endothelin axis polymorphisms in patients with scleroderma.

  2006cites this paper
• Rituximab: Applications in dermatology

  2006cites this paper
• The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?

  2006cites this paper
• Skin-2 Mouse: A Model for Scleroderma Demonstration of Autoimmunity in the Tight

  2005influential citation